VX-702

Catalog No.S6005

VX-702 Chemical Structure

Molecular Weight(MW): 404.3

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 110 In stock
USD 370 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Reduction of IL-10 expression due to p38 inhibition is observed also in CpG-stimulated B cells and using VX-702. B cells were pre-treated with 10 uM of VX-702 for 1 h and stimulated with LPS or CpG for 24 or 48 h. Bar graphs indicate mean (±SEM) IL-10 concentrations at 48 h from n = 4 (LPS) and n = 3 (CpG) experiments. Significant differences against the no inhibitor condition were calculated using a paired Student's t-test and indicated as follows: *p < 0.05, ***p < 0.001.

    Mol Immunol 2014 62(2), 266-76. VX-702 purchased from Selleck.

     Bone marrow derived macrophages were pre-treated with the indicated concentrations of VX702 for 1h prior to LPS treatment (100 ng/ml).  TNF-a production was analyzed 24h later.

    Lee lay hoon from National University of Singapore. VX-702 purchased from Selleck.

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.
Features Highly selective, orally active inhibitor of p38 MAPK.
Targets
p38α [1]
(Cell-free assay)
4 nM-20 nM
In vitro

Pre-incubation of platelets with VX-702 (1 μM) completely or partially inhibits p38 activation (IC50 4 to 20 nM) induced by platelet agonists including thrombin, SFLLRN, AYPGKF, U46619 and collagen. VX-702 shows no effect on platelet aggregation induced by any of the p38 MAPK agonists in the presence or absence of anti-platelet therapies. [1] VX-702 inhibits the production of IL-6, IL-1β and TNFα (IC50 = 59, 122 and 99 ng/mL, respectively) in a dose-dependent manner. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HOP-62 cell M{HrTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF;wNYRKdmirYnn0bY9vKG:oIHj1cYFvKEiRUD22NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODF3NEOg{txO NH;YeWhUSU6JRWK=
human NCI-H720 cell NGrae|JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYDJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KN{KwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xOTZ6MjFOwG0> MkHyV2FPT0WU
JVM-2 cell NETXPZBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWnJcohq[mm2aX;uJI9nKGi3bXHuJGpXVS1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6wPFMh|ryP M37ueXNCVkeHUh?=
human NCI-H69 cell NHXxT|FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4\JcGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi2PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODl7NEGg{txO M1rhNHNCVkeHUh?=
human BV-173 cell NXH2N2s4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFna[3BKdmirYnn0bY9vKG:oIHj1cYFvKEKYLUG3N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTF|OE[g{txO NXn5d2xTW0GQR1XS
human KU812 cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlLoTY5pcWKrdHnvckBw\iCqdX3hckBMXThzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVI1QDhizszN NXLOXWpCW0GQR1XS
human DU-145 cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWHJcohq[mm2aX;uJI9nKGi3bXHuJGRWNTF2NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVQ2PTRizszN MWnTRW5ITVJ?
KARPAS-45 cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlG2TY5pcWKrdHnvckBw\iCqdX3hckBMSVKSQWOtOFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF2OEK2JO69VQ>? NYnPbW1yW0GQR1XS
human AGS cell Mon0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVjJcohq[mm2aX;uJI9nKGi3bXHuJGFIWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUWyOVEh|ryP NI[yWlVUSU6JRWK=
human MOLT-13 cell M{[3eGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGfYdWdKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStNVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF3OUixJO69VQ>? M2XLV3NCVkeHUh?=
human NCI-H209 cell NGXFSlRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2jpSmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF5NUig{txO M3\sWHNCVkeHUh?=
human CTV-1 cell M{DwVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2[2WmlvcGmkaYTpc44hd2ZiaIXtZY4hS1SYLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE5Ozh7IN88US=> MUnTRW5ITVJ?
LU-139 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MojoTY5pcWKrdHnvckBw\iCqdX3hckBNXS1zM{mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE6PDN3IN88US=> M{\lV3NCVkeHUh?=
ML-2 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYTJcohq[mm2aX;uJI9nKGi3bXHuJG1NNTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkKyOlYyKM7:TR?= MUjTRW5ITVJ?
human K5 cell NGjpV5BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4fKSGlvcGmkaYTpc44hd2ZiaIXtZY4hUzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkKyPVE4KM7:TR?= MWnTRW5ITVJ?
human SBC-1 cell NV3xVlRIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWjFU4FWUW6qaXLpeIlwdiCxZjDoeY1idiCVQlOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN4MjFOwG0> M2PwNHNCVkeHUh?=
human COR-L88 cell M3TsRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2DoS2lvcGmkaYTpc44hd2ZiaIXtZY4hS0:ULVy4PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzN2ODFOwG0> NXnQdpFkW0GQR1XS
human KY821 cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXi4cI5{UW6qaXLpeIlwdiCxZjDoeY1idiCNWUiyNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzl4MEOg{txO M1rnNXNCVkeHUh?=
human HCC2218 cell M4jnU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYTJcohq[mm2aX;uJI9nKGi3bXHuJGhESzJ{MUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQ6PzJ6IN88US=> MXPTRW5ITVJ?
human ECC10 cell NHrL[lFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH25cmxKdmirYnn0bY9vKG:oIHj1cYFvKEWFQ{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE43PTN6OTFOwG0> M3jwTHNCVkeHUh?=
human EW-3 cell NVrkVG5tT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkLkTY5pcWKrdHnvckBw\iCqdX3hckBGXy1|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD62OlYyOSEQvF2= MX\TRW5ITVJ?
human EW-18 cell M2LKWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWjPUlRQUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2xPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzR4N{mg{txO NIrjWYFUSU6JRWK=
human UACC-257 cell NFzuZYpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXzudJVFUW6qaXLpeIlwdiCxZjDoeY1idiCXQVPDMVI2PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwMkCzNlYh|ryP NWn1SXZTW0GQR1XS
human G-361 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M13mdGlvcGmkaYTpc44hd2ZiaIXtZY4hTy1|NkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlQ6PTF7IN88US=> NHjqNohUSU6JRWK=
human HMV-II cell NHHafJRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NG[0N2hKdmirYnn0bY9vKG:oIHj1cYFvKEiPVj3JTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPzdzOESg{txO NUW0SppVW0GQR1XS
human DEL cell MoflS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVrJcohq[mm2aX;uJI9nKGi3bXHuJGRGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwMkC3NFQh|ryP M{ezS3NCVkeHUh?=
human IGROV-1 cell NVLTSY1mT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX3Jcohq[mm2aX;uJI9nKGi3bXHuJGlIWk:YLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlQ{OTh6IN88US=> MlzjV2FPT0WU
human SK-OV-3 cell M{nXemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1rOS2lvcGmkaYTpc44hd2ZiaIXtZY4hW0tvT2[tN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPjF4OUeg{txO NHnQ[lRUSU6JRWK=
human LAMA-84 cell M2XKR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1O2[WlvcGmkaYTpc44hd2ZiaIXtZY4hVEGPQT24OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPzF{OESg{txO MnrGV2FPT0WU
human NCI-H510A cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4X1bWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi1NVBCKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi57MkWyOkDPxE1? NEW1bGtUSU6JRWK=
human CP66-MEL cell Mn;nS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkHsTY5pcWKrdHnvckBw\iCqdX3hckBEWDZ4LV3FUEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQTN3NUmg{txO MmrUV2FPT0WU
human HAL-01 cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIC5bJhKdmirYnn0bY9vKG:oIHj1cYFvKEiDTD2wNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOjd7MUig{txO MUPTRW5ITVJ?
human RS4-11 cell  M4\VNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlTXTY5pcWKrdHnvckBw\iCqdX3hckBTWzRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlcxPTd|IN88US=> Mkn4V2FPT0WU
human RPMI-8226 cell M3j1cmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3PjO2lvcGmkaYTpc44hd2ZiaIXtZY4hWlCPST24NlI3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy56MkO3OkDPxE1? MYfTRW5ITVJ?
human NCI-H82 cell NWXwS5lYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkjFTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{45QTNyNTFOwG0> NXnJW|c3W0GQR1XS
human NY cells M33veWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXfJcohq[mm2aX;uJI9nKGi3bXHuJG5[KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5{N{[zO{DPxE1? MV7TRW5ITVJ?
human MDA-MB-361 cell MmXBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVfJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2zOlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjR|MUW4JO69VQ>? MYTTRW5ITVJ?
human MOLT-4 cell NYnGTXJkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{T4ZWlvcGmkaYTpc44hd2ZiaIXtZY4hVU:OVD20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46QTF7MzFOwG0> NVrLO|NiW0GQR1XS
human DU-4475 cell M1vwR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MX\Jcohq[mm2aX;uJI9nKGi3bXHuJGRWNTR2N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlA2PTZ3IN88US=> MYPTRW5ITVJ?
human ESS-1 cell M2HPS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{fqVWlvcGmkaYTpc44hd2ZiaIXtZY4hTVOVLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlI6OTd7IN88US=> M{LiNXNCVkeHUh?=
human NCI-H1299 cell NVP0bo1GT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1P2XWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixNlk6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS53M{CzN{DPxE1? NH3QZ2pUSU6JRWK=
human COLO-684 cell MomyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXnNfnlHUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVY5PCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNUixOlUh|ryP M1fY[XNCVkeHUh?=
human MV-4-11 cell MlrPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoLhTY5pcWKrdHnvckBw\iCqdX3hckBOXi12LUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU44OTF7OTFOwG0> NWDkVpR6W0GQR1XS
human D-542MG cell NID1WoRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXO5WFFNUW6qaXLpeIlwdiCxZjDoeY1idiCGLUW0Nm1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi5|OUK3NkDPxE1? MkSyV2FPT0WU
human A4-Fuk cell NYTU[WxtT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXTQc2c4UW6qaXLpeIlwdiCxZjDoeY1idiCDND3GeYsh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjR|Nk[yJO69VQ>? NETCdFhUSU6JRWK=
human HL-60 cell M4Lme2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkniTY5pcWKrdHnvckBw\iCqdX3hckBJVC14MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuOVIzOTJizszN MVvTRW5ITVJ?
human NCI-H526 cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXXrVnpvUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFUzPiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwNUm4NFEh|ryP MYXTRW5ITVJ?
human L-363 cell M1PJcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlWyTY5pcWKrdHnvckBw\iCqdX3hckBNNTN4MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuO|kzPTJizszN MVnTRW5ITVJ?
human A388 cell NEPRTYhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoHITY5pcWKrdHnvckBw\iCqdX3hckBCOzh6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz64NFM5PCEQvF2= NH\sWllUSU6JRWK=
human MS-1 NHTLZ21Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1\ZV2lvcGmkaYTpc44hd2ZiaIXtZY4hVVNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuPFM1PjVizszN NX3YUnhbW0GQR1XS
human JAR cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnjYTY5pcWKrdHnvckBw\iCqdX3hckBLSVJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15Lki0PVI{KM7:TR?= Mmq3V2FPT0WU
human TI-73 cell M1fYfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIT6eZhKdmirYnn0bY9vKG:oIHj1cYFvKFSLLUezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PE4xPjJ{IN88US=> M3i1cXNCVkeHUh?=
human CTB-1 cell NWr6TnhQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlS3TY5pcWKrdHnvckBw\iCqdX3hckBEXEJvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUiuNVc5OjVizszN MY\TRW5ITVJ?
human SK-NEP-1 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWPCfGtKUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3OSXAuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFzLkOwN|gh|ryP Ml[4V2FPT0WU
human HT-29 cell MlXyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1\F[2lvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xN{46OTFzIN88US=> NVnBemFyW0GQR1XS
human NCI-H1092 cell Mnv2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGPkdI9KdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVA6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF2LkOxPEDPxE1? MVrTRW5ITVJ?
human KMOE-2 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGtOV0VvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG0MlYyPzhizszN MX;TRW5ITVJ?
human EM-2 cell M4jQRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXLkfmhoUW6qaXLpeIlwdiCxZjDoeY1idiCHTT2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVUvOjh2MTFOwG0> MYfTRW5ITVJ?
human RT-112 cell NVK3RpluT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYTJcohq[mm2aX;uJI9nKGi3bXHuJHJVNTFzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG1MlM6QDRizszN NUfRbI5IW0GQR1XS
human DB cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWHJcohq[mm2aX;uJI9nKGi3bXHuJGRDKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTVwOEWxN{DPxE1? NXSwS|JUW0GQR1XS
human NCI-H1770 cell NVuwd5BwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NInaU2dKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVc4OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7 M{DRRnNCVkeHUh?=
human CAL-54 cell MkXnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M37KSWlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUW0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVYvPzNizszN MmTkV2FPT0WU
human NB14 cell NVv2[YM1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3LoSWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG3MlY{QTVizszN NYe1UW11W0GQR1XS
human RPMI-7951 cell MkWzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NG\5[5FKdmirYnn0bY9vKG:oIHj1cYFvKFKSTVmtO|k2OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF7LkG3PFMh|ryP NHfZdHZUSU6JRWK=
human T47D cell MnTYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmL1TY5pcWKrdHnvckBw\iCqdX3hckBVPDeGIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkGuNlI1OyEQvF2= NGDMbZNUSU6JRWK=
human A549 cell NET0eHVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3vCNWlvcGmkaYTpc44hd2ZiaIXtZY4hSTV2OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKxMlI5OTFizszN NXn0b3JYW0GQR1XS
human A2780 cell M2DzXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFHh[GFKdmirYnn0bY9vKG:oIHj1cYFvKEF{N{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlEvQDJ{NTFOwG0> NYf0[5h3W0GQR1XS
human SK-MEL-24 cell NGDWWWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{\lRWlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVI1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzNwMEOxNUDPxE1? MV;TRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo The half-life of VX-702 is 16 to 20 hours, with a median clearance of 3.75 L/h and a volume of distribution of 73 L/kg. Both AUC and Cmax values are dose proportional for VX-702, which is predominantly cleared renally. [2] VX-702 (at a dose of 0.1 mg/kg twice daily) has an equivalent effect as that of methotrexate (0.1 mg/kg). In addition, VX-702 (5 mg/kg twice daily) also has an equivalent effect as prednisolone (10 mg/kg once daily), as measured by percentage inhibition of wrist joint erosion and inflammation score. [3] VX-702 selectively inhibits activation of p38 MAPK after ischemia with no effects on ERKs and JNKs. The MI/AAR ratio is significantly reduced in the 50 mg/kg group compared with the 5 mg/kg and vehicle groups.[4]

Protocol

Solubility (25°C)

In vitro DMSO 81 mg/mL (200.34 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 404.3
Formula

C19H12F4N4O2

CAS No. 745833-23-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00395577 Completed Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated November 2006 Phase 2
NCT00205478 Completed Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated June 2005 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products

Tags: buy VX-702 | VX-702 supplier | purchase VX-702 | VX-702 cost | VX-702 manufacturer | order VX-702 | VX-702 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID